CA2151240A1 - Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse - Google Patents
Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuseInfo
- Publication number
- CA2151240A1 CA2151240A1 CA002151240A CA2151240A CA2151240A1 CA 2151240 A1 CA2151240 A1 CA 2151240A1 CA 002151240 A CA002151240 A CA 002151240A CA 2151240 A CA2151240 A CA 2151240A CA 2151240 A1 CA2151240 A1 CA 2151240A1
- Authority
- CA
- Canada
- Prior art keywords
- estrogen
- bisphosphonate
- bone
- bone loss
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99641892A | 1992-12-23 | 1992-12-23 | |
US996,418 | 1992-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2151240A1 true CA2151240A1 (fr) | 1994-07-07 |
Family
ID=25542895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002151240A Abandoned CA2151240A1 (fr) | 1992-12-23 | 1993-12-17 | Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0675723A4 (fr) |
JP (1) | JPH08505142A (fr) |
AU (1) | AU5953894A (fr) |
CA (1) | CA2151240A1 (fr) |
WO (1) | WO1994014455A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2065313T5 (es) * | 1993-05-15 | 2004-01-01 | Roche Diagnostics Gmbh | Tableta con biodisponibilidad mejorada que contiene acido diclorometilendifosfonico como sustancia activa. |
US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
UA41909C2 (uk) * | 1994-07-22 | 2001-10-15 | Елі Ліллі Енд Компані | Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат |
US5780455A (en) * | 1994-08-24 | 1998-07-14 | Merck & Co., Inc. | Intravenous alendronate formulations |
EP0824341A4 (fr) * | 1995-05-12 | 1999-07-07 | Merck & Co Inc | Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels |
US5545635A (en) * | 1995-05-23 | 1996-08-13 | Eli Lilly And Company | Inhibiting bone loss with equilenin |
US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
AU712710B2 (en) * | 1996-05-17 | 1999-11-11 | Merck Sharp & Dohme Corp. | Effervescent bisphosphonate formulation |
EP1378234A1 (fr) * | 1996-05-17 | 2004-01-07 | MERCK & CO. INC. | Formulation de bisphosphonate effervescente |
US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
JP2001507338A (ja) * | 1996-11-25 | 2001-06-05 | メルク エンド カンパニー インコーポレーテッド | 疾患を治療するために同時投与されるアンドロゲン物質とビスホスホン酸物質 |
US6376477B2 (en) | 1996-11-25 | 2002-04-23 | Merck & Co., Inc. | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism |
DE19719680A1 (de) | 1997-05-09 | 1998-11-19 | Boehringer Mannheim Gmbh | Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz |
US6555529B1 (en) * | 1997-12-25 | 2003-04-29 | Toray Industries, Inc. | Remedies for intramedullary diseases |
PT1135140E (pt) * | 1998-12-04 | 2005-10-31 | Roche Diagnostics Gmbh | Utilizacao de ibandronato para a promocao da integracao ossea de endoproteses |
EP1210138A4 (fr) * | 1999-04-22 | 2003-05-07 | Hydro Med Sciences Inc | Administration regulee de bisphosphonates |
AUPQ232599A0 (en) * | 1999-08-19 | 1999-09-09 | Royal Alexandra Hospital For Children, The | Drug for treating fractures |
FR2803521B1 (fr) * | 2000-01-12 | 2002-10-25 | Ceva Sante Animale | Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose |
US7425549B2 (en) * | 2001-02-06 | 2008-09-16 | The Royal Alexandra Hospital For Children | Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
WO2002080933A1 (fr) * | 2001-04-03 | 2002-10-17 | The Royal Alexandra Hospital For Children | Medicament a utiliser en matiere de greffe osseuse |
AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
WO2003057136A2 (fr) | 2001-12-24 | 2003-07-17 | Teva Pharmaceutical Industries Ltd. | Forme posologique avec pastille noyau de principe actif enrobee dans un corps annulaire comprime de poudre ou de substance granulaire, et procede et outils pour la production de cette forme posologique |
US7488496B2 (en) | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
EP1508343B1 (fr) * | 2003-08-21 | 2015-11-04 | AddBIO AB | Implant revêtu de bisphosphonate et son procédé de fabrication |
US8940320B2 (en) | 2005-10-27 | 2015-01-27 | Thommen Medical Ag | Dental implant and production method for said implant |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3623397A1 (de) * | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
DE4029499A1 (de) * | 1990-09-18 | 1992-03-19 | Boehringer Mannheim Gmbh | Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
EP0496520A1 (fr) * | 1991-01-22 | 1992-07-29 | Merck & Co. Inc. | Agents actifs sur les os |
HU215124B (hu) * | 1991-02-26 | 1998-09-28 | Norwich Eaton Pharmaceuticals, Inc. | Eljárás csontritkulás (osteoporosis) kezelésére szolgáló ösztrogént és difoszfonátot tartalmazó, szinergetikus hatású gyógyszerkészítmények előállítására |
-
1993
- 1993-12-17 CA CA002151240A patent/CA2151240A1/fr not_active Abandoned
- 1993-12-17 AU AU59538/94A patent/AU5953894A/en not_active Abandoned
- 1993-12-17 EP EP94905419A patent/EP0675723A4/fr not_active Ceased
- 1993-12-17 WO PCT/US1993/012302 patent/WO1994014455A1/fr not_active Application Discontinuation
- 1993-12-17 JP JP6515312A patent/JPH08505142A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1994014455A1 (fr) | 1994-07-07 |
EP0675723A4 (fr) | 1998-08-05 |
EP0675723A1 (fr) | 1995-10-11 |
JPH08505142A (ja) | 1996-06-04 |
AU5953894A (en) | 1994-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2151240A1 (fr) | Administration de biophosphonate et d'oestrogene pour le traitement et la prevention de la perte osseuse | |
EP0756483B1 (fr) | Emploi de biphosphonates inhibant la resorption osseuse consecutive a l'implantation d'une prothese orthopedique | |
EP0635270B1 (fr) | Hormone parathyroide et raloxifène pour augmenter la masse d'os | |
JP2002529490A (ja) | 歯牙吸収性病変の阻害方法 | |
JP4989811B2 (ja) | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 | |
AU5973496A (en) | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices | |
US6399592B1 (en) | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss | |
US6376477B2 (en) | Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism | |
JP2002526412A (ja) | 跛行を処置するための医薬品製剤の製造におけるビスホスホン酸誘導体の使用 | |
EA000677B1 (ru) | Способ предотвращения остеопороза | |
CA2271664A1 (fr) | Agents androgene et bisphosphonique coadministres pour traiter des maladies | |
AU2005203308A1 (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis | |
AU9745901A (en) | Use of bisphosphonates for inhibiting bone resorption following implantation of orthopaedic prosthesis | |
AU3574799A (en) | Use of biphosphonates for inhibiting bone resorption following implantation of orthopedic prosthesis | |
MXPA96004968A (en) | Use of bisphosphonates to inhibit bone rebassion after the implantation of orthopedic protesis | |
Forde | Pharmacological Intervention in the Treatment of Osteoporosis: What's Old and What's New | |
MXPA97001526A (en) | Combined therapy to treat osteoporo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |